REG - ValiRx PLC - Broker Option - Fully Subscribed
RNS Number : 0505UValiRx PLC24 July 2020
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Broker Option - Fully Subscribed
London, UK., 24 July 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces that, further to the announcement made at 3.02pm on 23 July 2020, the Broker Option - a facility to allow existing shareholders to participate in the Fundraise on similar terms to the Placing announced, has been fully subscribed for by existing shareholders of the Company.
The Broker Option has raised £300,700 at a price of 7.5 pence per share through the issue of 4,009,334 new ordinary shares.
In the announcement made at 3.02pm on 23 July 2020 the shareholding of Gerry Desler, Chief Financial Officer of the Company, following the Subscription was erroneously stated as 1,941,875 representing 3.6% of the enlarged share capital. The shareholding following the Subscription should have stated 81,667 representing 0.2% of the enlarged share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 7073 2628
Suzanne Dilly
Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Jo Turner / Ludovico Lazzaretti
Tel: +44 (0) 20 7213 0880
Peterhouse Capital Limited (Sole Broker)
Duncan Vasey / Lucy Williams / Eran Zucker
Tel: +44 (0) 20 7469 0930
Notes for Editors
About ValiRx
ValiRx PLC accelerates the development of innovative medicines that enhance patient experience. We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDIOEKKQBNDBKDQOB
Recent news on ValiRx
See all newsREG - ValiRx PLC - Directorate Changes
AnnouncementREG - ValiRx PLC - Evaluation Agreement with Imperial College London
AnnouncementREG - ValiRx PLC - Board Re-structuring and update on requisition
AnnouncementREG - ValiRx PLC - Shareholder Requisition Notice
AnnouncementREG - ValiRx PLC - Proposed Appointment of Non-Executive Director
Announcement